Now or later? Switching therapies in metastatic breast cancer.
Saved in:
| Title: | Now or later? Switching therapies in metastatic breast cancer. |
|---|---|
| Authors: | Valenza C; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard University, Boston, MA, USA; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan 20141, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address: carmine.valenza@ieo.it., Regan MM; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard University, Boston, MA, USA., Burstein HJ; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard University, Boston, MA, USA. |
| Source: | The Lancet. Oncology [Lancet Oncol] 2026 Jul 13. Date of Electronic Publication: 2026 Jul 13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1474-5488 |
|---|---|
| DOI: | 10.1016/S1470-2045(26)00332-3 |
